AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22289235 — intervention group
Group type: EXPERIMENTAL
Intervention: Full kinematic chain manual and manipulative therapy (MMT) plus exercise
Number of subjects: 111
Study 22289235 — intervention group
Group type: COMPARATOR
Intervention: Targeted hip manual and manipulative therapy (MMT) plus exercise
Number of subjects: 111
Study 20798154 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (exercise program)
Number of subjects: 22
Study 20798154 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonwalking)
Number of subjects: 22
Study 19057270 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally until disease progression or intolerable toxicity
Number of subjects: 62
Study 19057270 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 62
Study 15909433 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gentamicin
Number of subjects: 0
Study 12824811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.75 g/kg mixed with diet soda)
Number of subjects: 20
Study 12824811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diet soda)
Number of subjects: 20
Study 10586830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (radiotherapy combined with systemic chemotherapy)
Number of subjects: 0
Study 10586830 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 9376450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 10)
Number of subjects: 15
Study 9376450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 15
Study 8013997 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion program
Number of subjects: 0
Study 2429622 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and vitamin C
Number of subjects: 97
Study 2429622 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C only (control group)
Number of subjects: 97
Study 30135032 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 0
Study 30135032 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 0
Study 27543527 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDT)
Number of subjects: 100
Study 27543527 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 100
Study 24801511 — intervention group
Group type: EXPERIMENTAL
Intervention: Visumax laser
Number of subjects: 22
Study 24801511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase laser
Number of subjects: 22
Study 24801511 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study 22275296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP enriched with GMP and G600
Number of subjects: 120
Study 22275296 — intervention group
Group type: COMPARATOR
Intervention: Lactose powder control
Number of subjects: 120
Study 22275296 — intervention group
Group type: COMPARATOR
Intervention: SMP control
Number of subjects: 120
Study 20628331 — intervention group
Group type: EXPERIMENTAL
Intervention: Score chart for predicting persistent complaints
Number of subjects: 468
Study 18322633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 mcg/day
Number of subjects: 44
Study 18322633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15731291 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg or 120 mg once a day, Naproxen 500 mg twice daily
Number of subjects: 387
Study 15731291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 15731291 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib or Naproxen
Number of subjects: 387
Study 12438293 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental history of type 2 diabetes
Number of subjects: 87
Study 12438293 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 87
Study 12438293 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 87
Study 12438293 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 87
Study 12438293 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS gene polymorphism
Number of subjects: 87
Study 10876435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic HME (BHME)
Number of subjects: 99
Study 10876435 — intervention group
Group type: COMPARATOR
Intervention: Nonbacteriostatic HME (NHME)
Number of subjects: 99
Study 7485925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg/promethazine 50 mg
Number of subjects: 304
Study 7485925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg/placebo
Number of subjects: 304
Study 7485925 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 100 mg/promethazine 50 mg
Number of subjects: 304
Study 7485925 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital 100 mg/placebo
Number of subjects: 304
Study 8398960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine injected intravenously
Number of subjects: 37
Study 8398960 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of physiologic saline diluted to 5 ml with 5% glucose (Control)
Number of subjects: 37
Study 3803416 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine (CBZ)
Number of subjects: 8
Study 3803416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29068756 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT+EX
Number of subjects: 100
Study 29068756 — intervention group
Group type: EXPERIMENTAL
Intervention: PL+EX
Number of subjects: 100
Study 29068756 — intervention group
Group type: COMPARATOR
Intervention: HILT
Number of subjects: 100
Study 29068756 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 100
Study 26169871 — intervention group
Group type: EXPERIMENTAL
Intervention: WWB + hiAXOS
Number of subjects: 0
Study 26169871 — intervention group
Group type: EXPERIMENTAL
Intervention: WWB + AXOS + RS
Number of subjects: 0
Study 26169871 — intervention group
Group type: EXPERIMENTAL
Intervention: WWB + hiRS
Number of subjects: 0
Study 26169871 — intervention group
Group type: COMPARATOR
Intervention: WWB
Number of subjects: 0
Study 25375848 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SN6AD2 IOL (+2.5 D near add)
Number of subjects: 62
Study 25375848 — intervention group
Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN6AD1 IOL (+3.0 D near add)
Number of subjects: 62
Study 22150410 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 100 μg
Number of subjects: 144
Study 22150410 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 200 μg
Number of subjects: 144
Study 22150410 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 300 μg
Number of subjects: 144
Study 22150410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144
Study 20332178 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group asthma education programme and locally adapted paediatric asthma guidelines
Number of subjects: 411
Study 20332178 — intervention group
Group type: COMPARATOR
Intervention: Adapted paediatric asthma guidelines
Number of subjects: 411
Study 20332178 — intervention group
Group type: COMPARATOR
Intervention: Unrelated educational intervention
Number of subjects: 411
Study 18524783 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 44
Study 18524783 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane
Number of subjects: 44
Study 15801332 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 252 microg
Number of subjects: 10
Study 15801332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15801332 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 10
Study 15801332 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 10
Study 12186344 — intervention group
Group type: EXPERIMENTAL
Intervention: Frialit-2 implants used in bone reconstruction
Number of subjects: 29
Study 10687523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10687523 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg loading dose and then 50 mg every 6 h)
Number of subjects: 49
Study 10687523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg loading dose and then 100 mg every 6 h)
Number of subjects: 49
Study 10687523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flurbiprofen and tramadol
Number of subjects: 49
Study 8579082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus rh‐GMCSF (3 micrograms/kg per day i.v.)
Number of subjects: 107
Study 8579082 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (ticarcillin‐clavulanate + netilmicin)
Number of subjects: 107
Study 8579082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus rh‐GMCSF
Number of subjects: 107
Study 8579082 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 107
Study 1937326 — intervention group
Group type: EXPERIMENTAL
Intervention: cefuroxime axetil 2 x 500 mg/d
Number of subjects: 128
Study 1937326 — intervention group
Group type: COMPARATOR
Intervention: ofloxacin 2 x 200 mg/d
Number of subjects: 128
Study 7270864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene (2 x 1 mg/kg)
Number of subjects: 20
Study 7270864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene
Number of subjects: 20
Study 30442467 — intervention group
Group type: EXPERIMENTAL
Intervention: Piriformis-sparing minimally invasive approach
Number of subjects: 100
Study 30442467 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior approach
Number of subjects: 100
Study 28797666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neurophysiology Education (PNE)
Number of subjects: 72
Study 26537182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 26537182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (females)
Number of subjects: 0
Study 26537182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (males)
Number of subjects: 0
Study 24091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg) every 3 weeks for up to 9 cycles followed by Bevacizumab (15 mg/kg) until disease progression
Number of subjects: 83
Study 24091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg)
Number of subjects: 83
Study 21846852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly (every 2 weeks)
Number of subjects: 225
Study 21846852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase alternating with placebo (monthly treatment group)
Number of subjects: 225
Study 21846852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 19425900 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 492
Study 19425900 — intervention group
Group type: COMPARATOR
Intervention: Abstaining from chewing gum
Number of subjects: 492
Study 19425900 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum / Abstaining from chewing gum
Number of subjects: 492
Study 17720071 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Adapt Advanced Optics IOL
Number of subjects: 80
Study 17720071 — intervention group
Group type: COMPARATOR
Intervention: Tecnis Z9000 IOL
Number of subjects: 80
Study 15480643 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy at energy level E1=0.15 mJ/mm2
Number of subjects: 90
Study 15480643 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy at energy level E2=0.44 mJ/mm2
Number of subjects: 90
Study 15480643 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 90
Study 11738123 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 42419
Study 11738123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor (pravastatin)
Number of subjects: 42419
Study 9740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy (average dose 23.4 mg/d)
Number of subjects: 2398
Study 9740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine with other treatments (average dose 35.7 mg/d)
Number of subjects: 2398
Study 9740604 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine monotherapy
Number of subjects: 2398
Study 9740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy (matched analysis)
Number of subjects: 2398
Study 8147338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (60 or 120 mg Fe/d)
Number of subjects: 80
Study 3170119 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 micrograms PGF2 alpha
Number of subjects: 45
Study 3170119 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms PGF2 alpha
Number of subjects: 45
Study 3170119 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms PGF2 alpha
Number of subjects: 45
Study 3170119 — intervention group
Group type: COMPARATOR
Intervention: Control (50 microliter of saline)
Number of subjects: 45
Study 31542290 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bioresorbable scaffolds
Number of subjects: 0
Study 28402704 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Large Balloon Dilation (EPLBD)
Number of subjects: 124
Study 28402704 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 124
Study 25159291 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie therapy
Number of subjects: 271
Study 25159291 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical agents
Number of subjects: 271
Study 23724572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis plus placebo
Number of subjects: 94
Study 23724572 — intervention group
Group type: COMPARATOR
Intervention: Diazepam plus muscle relaxation
Number of subjects: 94
Study 21038024 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 68
Study 21038024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPND) 400 µg twice daily (b.i.d.)
Number of subjects: 68
Study 21038024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18412295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in addition to best medical management
Number of subjects: 0
Study 18412295 — intervention group
Group type: COMPARATOR
Intervention: Best medical management alone
Number of subjects: 0
Study 16752139 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstaining participants
Number of subjects: 50
Study 16752139 — intervention group
Group type: COMPARATOR
Intervention: Smoking participants
Number of subjects: 50
Study 12921396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-effects computation with random treatment-by-center interaction
Number of subjects: 0
Study 12921396 — intervention group
Group type: COMPARATOR
Intervention: Fixed-effects, two-way analysis of variance
Number of subjects: 0
Study 10919680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate HFA 134a pMDIs (400, 1000, and 2000 microg doses)
Number of subjects: 23
Study 10919680 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate HFA 134a pMDIs (125 and 250 microg strengths)
Number of subjects: 23
Study 10919680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate HFA 134a pMDIs
Number of subjects: 23
Study 8828766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB system (HC group)
Number of subjects: 30
Study 8828766 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated oxygenator and uncoated CPB circuit (HO group)
Number of subjects: 30
Study 8828766 — intervention group
Group type: COMPARATOR
Intervention: Uncoated system (UC group)
Number of subjects: 30
Study 1533728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 1533728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3993041 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic exercise alone
Number of subjects: 123
Study 3993041 — intervention group
Group type: EXPERIMENTAL
Intervention: iodine therapy with iodine brine
Number of subjects: 123
Study 3993041 — intervention group
Group type: EXPERIMENTAL
Intervention: remedial exercise plus iodine brine therapy
Number of subjects: 123
Study 3993041 — intervention group
Group type: COMPARATOR
Intervention: rigidly controlled diabetic diet (common to all groups)
Number of subjects: 123
Study 29338568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pineapple flavored lactoferrin oral sachets 100 mg twice daily with health education (group A)
Number of subjects: 120
Study 29338568 — intervention group
Group type: COMPARATOR
Intervention: Total dose infusion (TDI) of low-molecular weight (LMW) iron dextran (group B)
Number of subjects: 120
Study 30213214 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey-only data collection
Number of subjects: 0
Study 30213214 — intervention group
Group type: COMPARATOR
Intervention: Administrative-only data collection
Number of subjects: 0
Study 27322478 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTP (Adipose Graft Transposition Procedure)
Number of subjects: 10
Study 27322478 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTP
Number of subjects: 10
Study 27322478 — intervention group
Group type: COMPARATOR
Intervention: CABG (Control)
Number of subjects: 10
Study 25424929 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 (live pentavalent rotavirus vaccine), 3 doses of 2 mL each, administered 28-42 days apart
Number of subjects: 300
Study 25424929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 25424929 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 (live pentavalent rotavirus vaccine)
Number of subjects: 300
Study 22456294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg administered 30 min before meals
Number of subjects: 12
Study 22456294 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin 50 mg administered immediately before meals
Number of subjects: 12
Study 22456294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg (both regimens)
Number of subjects: 12
Study 20626665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) group
Number of subjects: 0
Study 20626665 — intervention group
Group type: COMPARATOR
Intervention: No metabolic syndrome (non-MetS) group
Number of subjects: 0
Study 20626665 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with MetS compared to those without MetS
Number of subjects: 0
Study 20626665 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of components of MetS
Number of subjects: 0
Study 17621619 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for OAB
Number of subjects: 0
Study 17621619 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (lifestyle interventions, modification of fluid intake, physiotherapy including bladder retraining)
Number of subjects: 0
Study 17621619 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 15647406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 800 microg
Number of subjects: 18
Study 15647406 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 1000 microg
Number of subjects: 18
Study 12642201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined informative and physical rehabilitation program
Number of subjects: 0
Study 12642201 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative groups (information and information+physical training)
Number of subjects: 0
Study 12642201 — intervention group
Group type: EXPERIMENTAL
Intervention: All programs (informative, physical, combined)
Number of subjects: 0
Study 12642201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination program or information alone
Number of subjects: 0
Study 10573067 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day of G-CSF
Number of subjects: 172
Study 10573067 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg/day of G-CSF
Number of subjects: 172
Study 10573067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 8915746 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 24
Study 8915746 — intervention group
Group type: EXPERIMENTAL
Intervention: ABV (doxorubicin, bleomycin, and vincristine)
Number of subjects: 24
Study 1888645 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg daily
Number of subjects: 5
Study 1888645 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 600 mg four times daily
Number of subjects: 5
Study 1888645 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 300 mg daily
Number of subjects: 5
Study 1888645 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 600 mg four times daily
Number of subjects: 5
Study 1888645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6139317 — intervention group
Group type: EXPERIMENTAL
Intervention: Timiperone
Number of subjects: 88
Study 6139317 — intervention group
Group type: COMPARATOR
Intervention: Clocapramine
Number of subjects: 88
Study 30783071 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPS + TAU
Number of subjects: 80
Study 30783071 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 80
Study 30306759 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 100000
Study 30306759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100000
Study 27309266 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser for 10 seconds
Number of subjects: 0
Study 27309266 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser for 30 seconds
Number of subjects: 0
Study 27309266 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser for 10 seconds
Number of subjects: 0